liothyronine Side Effects
Also known as: Cytomel
Analysis of 8,408 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
8,408
Death-Related
195
2.3% of reports
Hospitalizations
1,457
17.3% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 195 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 92 |
| COMPLETED SUICIDE | 23 |
| DYSPNOEA | 15 |
| FALL | 13 |
| TOXICITY TO VARIOUS AGENTS | 12 |
| NAUSEA | 10 |
| OFF LABEL USE | 10 |
| PYREXIA | 9 |
| SEPSIS | 9 |
| CARDIAC ARREST | 8 |
| ATRIAL FIBRILLATION | 7 |
| COUGH | 7 |
| DIARRHOEA | 7 |
| PAIN | 7 |
| PLEURAL EFFUSION | 7 |
| RENAL FAILURE | 7 |
| RESPIRATORY FAILURE | 7 |
| VOMITING | 7 |
| CONDITION AGGRAVATED | 6 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 6 |
Reactions in Hospitalization Reports
Top reactions in 1,457 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| HEADACHE | 317 |
| HYPERTENSION | 281 |
| DYSPNOEA | 268 |
| HYPOTHYROIDISM | 243 |
| ASTHMA | 240 |
| CARDIAC DISORDER | 238 |
| GASTROOESOPHAGEAL REFLUX DISEASE | 227 |
| BURNING SENSATION | 222 |
| THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 222 |
| FIBROMYALGIA | 219 |
| CARPAL TUNNEL SYNDROME | 217 |
| SLEEP APNOEA SYNDROME | 214 |
| RHINITIS ALLERGIC | 213 |
| BLOOD TEST ABNORMAL | 212 |
| SENSITISATION | 211 |
| POLYCYSTIC OVARIES | 209 |
| SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION | 200 |
| LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES | 191 |
| RENAL DISORDER | 185 |
| EJECTION FRACTION | 176 |
Nearby — Related Medications
What the FAERS Data Reveals About liothyronine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 8,408 voluntary reports linked to liothyronine and its brand equivalents (Cytomel), spanning 2004 through 2025. Of those, 195 (2.3%) listed death as an outcome and 1,457 (17.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 89% were female and 11% male; age distribution skews toward 45-64, with 2,556 reports in that bracket. The single most reported reaction is drug ineffective with 936 submissions, followed by headache and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.